Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Monday, November 30 2009 7:57pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > Geron Corporation Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Geron Corporation Company Profile
Not far from the center of the controversy over human embryonic stem cell (hESC) research is Geron. The company hopes to parlay its work into viable therapies for various diseases and conditions. One of the company's lead products is a hESC therapy called GRNOPC1 for spinal cord injury which was approved to enter the world's first hESC human clinical trials until the FDA put a hold on the trials while the agency reviewed new data. Geron is also focused on anticancer drug candidate GRN163L, which inhibits telomerase, an enzyme that may prolong cellular life and prevents apoptosis (programmed cell death). Geron has been in business since 1992 and has subsidiaries in Scotland and Hong Kong.
Headlines for Geron Corporation
[external] 4-Star Stocks Poised to Pop: Cytori Therapeutics
at Motley Fool - Fri Nov 27
[external] RPT-Company seeks to test stem cells for blindness
at Reuters - Thu Nov 19
Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
Business Wire - Thu Nov 19
Geron to Present at LCM Healthcare Conference
Business Wire - Mon Nov 16
More Headlines...
More on Geron Corporation
Quote SEC
Chart Msgs
News Insider
Profile Financials
Reports Analyst Ratings
Research    
Contact Information
Address: 230 Constitution Dr.
Menlo Park, CA 94025
Phone:650-473-7700
Fax:650-473-7750
Financial Highlights
Fiscal Year End:December
Revenue (2008):2.80 M
Revenue Growth (1 yr):(-63.20%)
Employees (2008):159
Employee Growth (1 yr):13.60%
Key People
Chairman: Alexander E. (Alex) Barkas
President, CEO, and Director; President, Oncology: Thomas B. Okarma
EVP, CFO, Treasurer, and Secretary: David L. Greenwood
Industry Information
Sector: Healthcare
Industry: Drug Manufacturers - Other
Top Competitors
GlaxoSmithKline Pharmaceuticals Limited
StemCells, Inc. (stem)
ViaCord
 


Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2009 Morningstar, Inc. All Rights Reserved. Company information © 2009 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2009, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo! nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo! site, a user agrees not to redistribute the information found therein.

Questions or Comments?